JSC Olainfarm Strengthens the Boards of Several Daughter Companies
Board of JSC Olainfarm has decided to make some changes to Management Boards of Silvanols LLC, Latvijas Aptieka LLC and Tonus Elast LLC.
Larisa Podlesnaja has left the Management Board of Tonus Elast to continue in Group of Internal Audit of JSC Olainfarm. Mrs. Podlesnaja will be replaced by Mr. Salvis Lapins, a long-term Board member of JSC Olainfarm, who currently is advising to Olainfarm’s Management Board.
As a long-term IR and Business Development officer, Mr. Lapins is very highly valued by shareholders and investors. Professional experience of Mr. Lapins will be a valuable asset for “Tonus Elast”.
Management Board of Silvanols will now consist of four members as Mr. Ingus Balandins is elected to the Board of the company. Mr. Balandins is well known among the industry professionals and has proven his abilities as founder and CEO of Franceska Vet LLC.
Board of Latvijas Aptieka will now consist of six members. Sanita Trautmane will no longer be a member of the Board, and Sintija Zange and Alla Cudovska, two experienced pharmacists, will join the remaining Board members as well as Zanete Eihmane, who has a long term experience in managing medical products retail company.
Changes to the Boards as well as respective changes to Articles of the mentioned daughter companies have been submitted to Register of Enterprises of the Republic of Latvia.
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 50 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Member of the Management Board
Phone +371 28698449
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)